Table 3.
Comparisons of adverse events in different trials.
| Bianchi Porro et al. [8] | Montrone et al. [6] | Jajić et al. [4] | p value | ||||
|---|---|---|---|---|---|---|---|
| AMG | Diclofenac | AMG | Piroxicam | AMG | Celecoxib | ||
| Patients evaluated, n | 32 | 32 | 49 | 50 | 85 | 95 | |
| GI symptoms, n (%) | 17 (53.1) | 14 (43.8) | 18 (36.7) | 20 (40) | 45 (52.9) | 57 (60) | >0.05 |
| Serious AEs related to the drug leading to withdrawal, n (%) | 3 (9.4) | 5 (15.6) | 2 (4.1) | 9 (18) | 0 (0) | 1 (1.1) | <0.051 |
| Cases of severe gastric and/or duodenal ulcer after treatment, n (%) | 1 (3.1) | 8 (25) | NE | 4 (4.7) | 10 (10.5) | <0.05 | |
| Patients with very high endoscopy score, n (%) | 4 (12.5) | 14 (43.8) | NE | 21 (24.7) | 21 (22.1) | <0.05 | |
NE: not evaluated.
1Additionally post hoc test was performed which gave similar results.